tradingkey.logo

BioMarin Pharmaceutical Inc <BMRN.OQ> expected to post earnings of 71 cents a share - Earnings Preview

ReutersApr 29, 2025 8:36 PM
  • BioMarin Pharmaceutical Inc BMRN.OQ BMRN.O is expected to show a rise in quarterly revenue when it reports results on May 1 for the period ending March 31 2025

  • The Novato California-based company is expected to report a 14.2% increase in revenue to $740.72 million from $648.83 million a year ago, according to the mean estimate from 23 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for BioMarin Pharmaceutical Inc is for earnings of 71 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 23 "strong buy" or "buy," 6 "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for BioMarin Pharmaceutical Inc is $94.50​, above​ its last closing price of $62.98. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

0.52

0.53

0.64

Beat

20.8

Sep. 30 2024

0.50

0.52

0.55

Beat

6.3

Jun. 30 2024

0.37

0.35

0.56

Beat

60.4​

Mar. 31 2024

0.36

0.35

0.46

Beat

33.3

​​Dec. 31 2023

0.23

0.23

0.18

Missed

-22.9

Sep. 30 2023

0.22

0.23

0.21

Missed

-10.3​

Jun. 30 2023

0.23

0.23

0.29

Beat

24.5

Mar. 31 2023

0.21

0.18

0.27

Beat

50.5

This summary was machine generated April 29 at 20:36 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI